Biogen tau therapy data and FDA clears Sanofi wearable injector as biotech news heats up

Researchers at a recent pancreatic cancer conference highlighted the potential of daraxonrasib, while an Alzheimer’s gathering placed tau‑targeting therapies at the forefront of discussion.

In the United States, the Department of Health and Human Services began drafting national guidance aimed at safely tapering selective serotonin reuptake inhibitors.

The FDA also issued clearance for Sanofi’s wearable injector device intended to deliver a myeloma treatment, marking a regulatory step for the technology.